PDSB
PDSB clinical trials: PDS Biotechnology Corp
Every trial on ClinicalTrials.gov where PDS Biotechnology Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PDSB on the catalyst calendar · PDSB registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026Actual | NCT06790966Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPDS Biotechnology Corp. · Recurrent Head and Neck Cancer | PDSBLead | Phase 3 | Terminated | Locked | Locked | Locked |
| May 14, 2025Actual | NCT04260126Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCPDS Biotechnology Corp. · Metastatic Head and Neck Cancer | PDSBLeadMRKCollaborator | Phase 2 | Completed | Locked | Locked | Locked |
| Dec 30, 2015Actual | NCT02065973An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101PDS Biotechnology Corp. · High-risk HPV Infection and Biopsy-proven CIN1 | PDSBLead | Phase 1 | Completed | Locked | Locked | Locked |
- Primary completion Aug 25, 2026ActualPhase 3NCT06790966Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPDS Biotechnology Corp. · Recurrent Head and Neck CancerTerminatedPDSBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 14, 2025ActualPhase 2NCT04260126Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCPDS Biotechnology Corp. · Metastatic Head and Neck CancerCompletedPDSBLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2015ActualPhase 1NCT02065973An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101PDS Biotechnology Corp. · High-risk HPV Infection and Biopsy-proven CIN1CompletedPDSBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner